RECOVERY & TISSUE REPAIR · THE NERVE QUESTION
Recovery & Tissue Repair Research Peptides, Measured Against Nerve
BPC-157, GHK-Cu and TB-500 are routinely described as nerve-repair compounds. This desk reads the seventeen sources behind that description and counts the substitutions standing between each study and a human nerve.
BPC-157
The lead compound here, and the one with the largest gap between reputation and record. Its best-characterised mechanism is the growth of new blood vessels, demonstrated in a chick membrane, a rat hindlimb and cultured human endothelial cells [4]. Its neural literature is a single review of rodent brain-gut work [7], written largely by the group that produced the underlying studies.
Read the record →
GHK-Cu
The copper-carrying tripeptide, and this hub's honest negative control. Neurons appear on its list of proposed cellular targets; not one of its five studies here measured a neuron. What they measured was wrinkle depth, hair count, gene expression and how much copper crosses a sheet of human skin [8][10][11][12].
Read the record →
TB-500
The only member with a neural efficacy study attached to it — a rat stroke experiment [14] — and the member for whom that study proves least, because it used the full-length parent protein rather than the seven-amino-acid fragment sold as TB-500.
Read the record →The honest summary
Three peptides come up again and again when people talk about healing nerves: BPC-157, GHK-Cu and TB-500. A peptide is a short chain of amino acids, the same building blocks proteins are made from.
This site collects what the published studies on these three actually measured, and it starts with the part most pages skip: not one of the seventeen studies listed here watched a peripheral nerve — a nerve in an arm, a leg, or anywhere outside the brain and spinal cord — regrow in a person. The closest thing in the whole index is a stroke experiment in rats [14].
Most of the rest measured tendon, skin, hair, stomach lining or blood vessels. Those are real results. They are not nerve results, and the difference is the entire point of this desk. Nothing here is medical advice, and no dose for a person is suggested anywhere on this site.
What "research peptides" means here — and what it does not
All three compounds on this site are sold for laboratory research use only. None is an approved medicine for any human indication, anywhere.
BPC-157 is not approved as a drug in any jurisdiction, and in 2023 the FDA placed it in a category of bulk substances it identified as not eligible for pharmacy compounding under 503A, pending further evaluation. TB-500 likewise has no approved therapeutic indication and is handled by suppliers as a research chemical with a veterinary history. GHK-Cu is the split case: topical Copper Tripeptide-1 is a legal cosmetic ingredient in the US, EU and UK with a long consumer safety record, while injectable or otherwise systemic GHK-Cu is an unapproved research chemical with no regulatory pathway.
Anti-doping status diverges just as sharply. BPC-157 is prohibited in sport at all times by the World Anti-Doping Agency under its non-approved-substances category, and TB-500 is prohibited under the peptide and growth-factor categories, with laboratory detection methods already published for it. GHK-Cu was not listed on the 2024–2025 Prohibited Lists, though WADA's catch-all category can still reach non-approved pharmacological substances.
One consequence runs through everything below: because these products move through unregulated channels, the identity, purity and actual content of any given vial are unverified outside a formal study. That uncertainty sits on top of every uncertainty in the science itself.
Why nerve is the hard case
Every reputation in the tissue-repair literature was earned somewhere specific. For these three peptides, those places are a fully transected rat Achilles tendon [6], a rat gastric ulcer [5], human facial skin under a cosmetic formulation [11][8], a rat hindlimb with its blood supply cut off [4], and a sheet of donated human skin in a diffusion apparatus [12].
Nerve is not on that list, and the record here reflects it. Across all seventeen sources indexed on this site, neural tissue appears in exactly three, and all three arrive qualified:
- A 2016 review of rodent brain-gut work, reporting that BPC 157 modulates serotonergic and dopaminergic systems and engages several intracellular signalling pathways [7]. It is a review, and it comes from the research group responsible for most of the primary literature it reviews.
- A 2014 dose-response study in rats given an embolic stroke, in which thymosin β4 improved neurological function [14]. The molecule used was the full-length parent protein, not the fragment sold as TB-500.
- A 2012 review listing central-nervous-system repair among the reasons thymosin β4 entered clinical development [15]. A rationale for trials is not the result of one.
Not one source reports a peripheral nerve regenerating. A compound that speeds the healing of a cut tendon in a rat has been shown to speed the healing of a cut tendon in a rat. Carrying that result across to a human nerve is an inference the studies themselves never make — and on this site it is written as an inference, every time.
The four substitutions
Every nerve-repair claim made for these three peptides rests on at least one of four swaps between what was studied and what is being claimed. Naming them is most of the work.
Species. A rat is standing in for a person. This is the substitution behind almost the entire BPC-157 literature — the tendon, ulcer, ischaemia and brain-gut findings are rodent work [6][5][4][7] — and behind the one neural efficacy result in the hub [14]. As of 2025, a narrative review counted only three small pilot studies of BPC-157 in humans and described rigorous large-scale trials as lacking [2].
Molecule. One compound is standing in for a related but different one. TB-500 is the seven-amino-acid fragment Ac-LKKTETQ; nearly all the encouraging efficacy research, including the rat stroke study [14] and the human safety study [16], used full-length thymosin β4, a protein several times its size. For GHK-Cu, the strongest controlled human result came from a combination product containing the peptide alongside 5-aminolevulinic acid, not from GHK-Cu alone [10].
Tissue. Skin, tendon, gut lining or muscle is standing in for nerve. This is the substitution nobody announces, and it is the one this site is organised around.
Route and compartment. A molecule delivered to one place is assumed to reach another. GHK-Cu's central formulation problem is that the free peptide barely crosses intact skin at all [8], which makes any assumption about it reaching a nerve a long way from measured.
How this desk grades a claim
Three rules, applied to every page here.
A finding is described in the species, tissue and molecule it was measured in, and those qualifiers stay attached to it — including in headings and summaries, where they are usually dropped. A result in rats is written as a result in rats.
Community reports are kept in their own clearly marked subsection on every compound page, labelled as anecdotal, never given a dose, and never allowed to stand in for a study.
An absence is reported as loudly as a presence. Where the literature has not measured something — human nerve regeneration, injectable GHK-Cu pharmacokinetics, the seven-mer's own efficacy — that gap is stated rather than filled with plausible-sounding mechanism.
What this leaves is a smaller set of claims than most pages on these compounds make, and a firmer one. The full side-by-side reading is on the comparison page; the sources are listed in full on the references page.